Collaborations’ Tab 

ACTICOR-BIOTECH, Paris, France. 

  • US Executive Medical Advisor 
  • US Clinical & Medical Operations 
  • Therapeutic Areas: Covid-19, Stroke 
  • [2019-To Date] 

Bionor Pharma, Oslo, Norway.  

  • Acting Chief Medical Officer [CMO]. 
  • Therapeutic Vaccines’ Clinical Development & Strategy. 
  • Design of pivotal global study. 
  • Medical Affairs. 
  • [2014-2017] 

DA VOLTERRA, Paris, France. 

  • Executive Consultant to CEO & Management Team. 
  • Drug development strategy countering Antibiotic Resistance 
  • [2012] 

DECOY Therapeutics, Cambridge MA.

  • Chairperson SAB:
  • Scientific Advisory Board.
  • Decoy Therapeutics has a dual mission: creating a rapid response broad based anti-viral platform for tomorrow’s viral pathogens and addressing today’s COVID-19 therapeutic gaps [2020 ongoing]

DEINOVE, Grables, France. 

  • Executive Medical Advisor, 
  • Clinical Trial in Infectious Diseases 
  • [2020-To Date] 

ENANTA Pharmaceuticals, Watertown MA, USA. 

  • [2019] 

Exl Pharma. New York, NY, USA.  

  • Professional Educational Courses on Medical & Scientific Affairs. 

GENZYME Corporation, Cambridge MA, USA. 

  • Medical Consultant, Pharmacovigilance Dept. 
  • [2012]. 

GSK/ViiV Healthcare, RTP NC, USA. 

  • A global specialist HIV company established by GlaxoSmithKline, Pfizer and Shinogi. 
  • [2012 – 2013]. 


  • Co-Founding Clinical Development Advisor. 
  • HemaCure is a translational stage company developing proprietary non-toxic autologous Hematopoietic stem cell (HSC) transplant method and a targeted cell-promoter combination aiming to the treatment of Parkinson’s disease and other conditions.. 
  • [2020-To Date]. 

InnaVirVax, Genopole™ Biotechnology Hub, Evry, France.  

  • Acting Chief Medical Officer [CMO] 
  • Acting Head of Translational Medicine 
  • Design and Clinical Operations for pivotal International study 
  • [2011-2014] 

METYS Pharmaceuticals, Basel, Switzerland. 


  • Building Sustainable Alliances to Provide Innovative Business & Science Solution 
  • [2013-2016] 

NOVARTIS, East Hannover, New Jersey, USA & Basel, Switzerland.

  • Medical Affairs [Medical Education, Publications, Phase IV]. 
  • [2012-2014] 

ORCHARD Therapeutics, London, UK. 

  • Gene Therapy in Orphan Diseases 

SEBASTIEN Biopharma, Cambridge MA, USA. 

  • SAB: Scientific Advisory Board Member [2020-2021]

STALLERGENES GREER, Antony, France & Boston MA, USA. 

  • Acting Global Head of Clinical Development & Medical Affairs 
  • Global Medical Affairs coverage: Asia Pacific – Canada – Europe (East/West) – USA. 
  • Clinical Development: Pivotal phase III study. 1,600 patients, 13 countries with 231 investigative sites, largest study of its kind in the therapeutic area []. 
  • [2017-2018] 

TRANSGENE, Strasbourg, France & Cambridge MA, USA. 

  • Therapeutic Vaccine Clinical Trial. 
  • [2016] 

VERSANTIS ETH, Zurich, Switzerland. 

YSOPIA Biosciences, Bordeaux, France. 

  • Unleashing Microbiome-based Therapies
  • Acting CMO: Chief Medical Officer.
  • [2020-2021].